GVHD-mediated ovarian insufficiency after SCT after nonmyeloablative conditioning. After intraperitoneal injection of BU (12 mg/kg) and CY (120 mg/kg) on day −7, mice were transplanted as in Figure 1A-D. Groups of mice were orally administered with 10 mg/kg PSL daily from day 0 to +14 after SCT, and thrice a week thereafter. (A) Clinical GVHD scores of diluent-treated (n = 5) and PSL-treated (n = 6) syngeneic recipients and diluent-treated (n = 12) and PSL-treated (n = 8) allogeneic recipients. Data from 1 of 5 similar experiments were shown as means ± SE. (B) Survivals of diluent-treated (n = 30) and PSL-treated (n = 14) syngeneic recipients and diluent-treated (n = 37) and PSL-treated (n = 18) allogeneic recipients were shown by combining results of 5 independent experiments. (C) Serum levels of AMH on day +21 in naive mice (n = 4) and syngeneic (n = 6) and allogeneic (n = 8) recipients of nonconditioned SCT and BU/CY-treated naive mice (n = 4) and syngeneic (n = 8) and allogeneic recipients of BU/CY-treated SCT were shown as means ± SE. (D) The numbers of oocytes ovulated on PMSG and hCG in syngeneic (n = 8) and allogeneic (n = 10) recipients are shown as means ± SE. (E) Mice were mated with naive male B6D2F1 mice repeatedly from day +14 to +150 and cumulated numbers of newborns from diluent-treated (n = 6) and PSL-treated (n = 8) syngeneic recipients and diluent-treated (n = 11) and PSL-treated (n = 8) allogeneic recipients were shown as means ± SE. (F) Female BALB/c mice were injected with 8 × 10⁶ splenocytes and 8 × 10⁶ bone marrow cells from syngeneic BALB/c or allogeneic B10.D2 donors after 6.5 Gy TBI on day 0. Bilateral ovaries harvested from naive BALB/c mice were transplanted under the kidney capsule on day +1. Serum levels of AMH in syngeneic (n = 10) and allogeneic (n = 11) recipients on day +112 are shown as mean ± SE. Data from 2 independent experiments were combined. *P < .05, **P < .01, ***P < .005.